FOXO4-DRI

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide designed to specifically trigger programmed cell death (apoptosis) in senescent cells - cells that no longer divide but also don't die. It belongs to the class of so-called senolytic agents, substances intended to rid the body of these 'zombie cells' that increasingly burden tissues with age.

The peptide is based on a section of the human FOXO4 protein but has been given a special modification: the D-retro-inverso technique. Here, the natural L-amino acids are replaced with their D-enantiomers, and the sequence is read backwards. This makes the peptide much more resistant to enzymatic breakdown in the body, while the spatial shape of the original protein is largely preserved - so it can still bind to the same target molecules [1,5].

FOXO4-DRI was developed in 2017 by a research group at the Erasmus University Medical Center in Rotterdam, who published their work in the journal Cell [1]. Since then, it has attracted considerable attention in the longevity and anti-aging community, even though it has only ever been tested in cell cultures and mouse models.

How is FOXO4-DRI used?

In all published studies, FOXO4-DRI was administered by injection - either intraperitoneally (into the abdominal cavity) or intravenously, both routes commonly used in mouse research [1,3,6]. Oral, nasal, or topical application has not been investigated in the scientific literature.

On the gray market - meaning among research chemical suppliers - FOXO4-DRI is typically sold as a lyophilized powder in vials and reconstituted by users with bacteriostatic water (BAC water) before being injected subcutaneously (under the skin). This practice is completely unsupported: there is not a single human study that has examined this route of administration, this dosage, or this regimen. If you're interested in the basics of mixing and storing, you can find them in the guides.

The regimen used in the studies is an intermittent senolytic protocol: not daily, but in short bursts with breaks in between. The idea is that senescent cells are eliminated once, and then time passes before the next round is needed - unlike peptides that are taken continuously.

From vial to use: reconstitution and dosing

Since there is no validated human dose, I can only document here what was used in animal studies and what is reported in the community - neither is a dosing recommendation.

Study dose (mouse)

The standard dose in all published mouse studies was 5 mg per kilogram of body weight, given as an intraperitoneal injection. The regimen varies slightly between studies:

If you were to transfer 5 mg/kg directly to a 75 kg human (which is methodologically questionable without allometric correction), that would be 375 mg per injection - an extremely high amount that, due to the complex D-amino acid synthesis, makes FOXO4-DRI one of the most expensive peptides of all. A proper allometric scaling (based on body surface area) would suggest significantly lower doses, but since no human studies exist, any value is speculation.

Community practice (unsupported)

Online forums and gray market suppliers typically offer vials with 1 mg, 5 mg, or 10 mg of FOXO4-DRI. The reported community practice includes subcutaneous injections, often in the range of 1-5 mg per dose, spread over several days. This information comes from forum posts and shop recommendations and is not backed by studies, clinical data, or regulatory review. Before you consider ordering, you should inform yourself about protection when ordering and vendor verification.

Reconstitution: example calculation

A typical 5 mg vial is reconstituted with 2 ml of BAC water. This gives a concentration of 2.5 mg/ml. With a standard insulin syringe (1 ml, 100 units), this corresponds to:

• 10 units = 0.25 mg
• 20 units = 0.50 mg
• 40 units = 1.00 mg

This calculation is purely mathematical and is not a recommendation - it only shows how to get from a vial to a specific amount. The question of whether these amounts are safe or effective for a human is unanswered.

How does FOXO4-DRI work?

To understand how FOXO4-DRI works, you need to know what senescent cells are and why they are a problem.

Senescent cells: the body's 'zombie cells'

When cells suffer damage - from DNA damage, oxidative stress, chemotherapy, or simply from many cell divisions - they can enter a state called cellular senescence. The cell no longer divides, but it also doesn't die. Instead, it remains in the tissue and secretes inflammatory signaling molecules (the so-called SASP - Senescence-Associated Secretory Phenotype). These signals can put neighboring healthy cells under pressure and drive inflammation.

With increasing age, these cells accumulate and are considered one of the reasons for tissue degeneration and age-related diseases. The body does have mechanisms to eliminate senescent cells via the immune system, but this process becomes less efficient with age.

The FOXO4-p53 trick

Normally, a protein called p53 - often referred to as the 'guardian of the genome' - would send a damaged cell into apoptosis (programmed cell death). Senescent cells, however, have a survival trick: they produce more of the protein FOXO4, which binds p53 and holds it in the cell nucleus. This blocks p53, and the cell survives even though it should die [1,5].

This is where FOXO4-DRI comes in: the peptide mimics part of the FOXO4 protein and competes with natural FOXO4 for binding to p53. When FOXO4-DRI wins, p53 is displaced from the nucleus. Without p53 in the nucleus, the cell cannot maintain its survival mechanism and dies - but only if it is senescent, because this FOXO4-p53 mechanism is only active in senescent cells [1].

A structural biology study by Bourgeois et al. (2025) has clarified that FOXO4-DRI binds more precisely to the disordered transactivation domain of p53 - a finding that helps explain why the peptide acts selectively and how it could be further optimized [5].

Why D-retro-inverso?

A normal peptide made of L-amino acids would be broken down within minutes in the body by enzymes (proteases) that are active everywhere in the blood and tissues. The D-retro-inverso modification swaps each amino acid for its mirror image (D-form) and simultaneously reverses the order of the chain.

That sounds drastic, but it has a clever effect: the three-dimensional shape of the binding site remains nearly identical because the side chains of the amino acids are arranged similarly in space. However, the proteases in the body no longer recognize the peptide and cannot break it down. This significantly extends the half-life, even though specific pharmacokinetic data in humans are lacking.

What do the studies say?

The evidence base for FOXO4-DRI consists exclusively of cell cultures and animal models. Here is an overview of the most important work:

The founding study: Baar et al. 2017

The original work, published in Cell, remains the most important reference to this day [1]. The researchers first showed in cell cultures that FOXO4-DRI selectively kills senescent cells while non-senescent cells remain unaffected. In naturally aged mice (>24 months), three injections (5 mg/kg, days 1, 3, and 5) led to measurable improvements: thicker fur, better kidney values, increased physical activity, and reduced markers of cellular senescence.

In a second model, mice were treated with doxorubicin (a chemotherapy drug), which triggers senescence - here too, FOXO4-DRI accelerated recovery. The study thus established both the mechanism of action and the dosing regimen that all subsequent studies have adopted.

Testosterone and Leydig cells: Zhang et al. 2020

This study investigated whether FOXO4-DRI can improve age-related testosterone insufficiency [3]. Aged mice (20-24 months) received 5 mg/kg i.p. on three alternating days. Thirty days later, the treated animals showed increased serum testosterone levels and improved markers of Leydig cells (the testosterone-producing cells in the testes). Body weight and testicular weight did not change - an indication of a targeted effect on senescent cells without general tissue alteration.

Human cartilage cells in vitro: Huang et al. 2021

This work is special in that it examined human tissue - but only in cell culture, not in living humans [2]. The researchers showed that FOXO4-DRI selectively removes senescent cells from expanded human chondrocytes (cartilage cells). This could be relevant for joint and cartilage regeneration, but it is far from clinical application.

Keloid fibroblasts: Kong et al. 2025

Keloids are excessive scar formations in which senescent fibroblasts play a role. Kong et al. showed that FOXO4-DRI sends these senescent fibroblasts into apoptosis through nuclear exclusion of phosphorylated p53 [4]. Here too, these are in vitro data with human tissue.

Endothelial cells and vascular aging: Hu et al. 2025

Hu et al. investigated the effect of FOXO4-DRI on endothelial cell senescence - that is, the aging of the cells lining blood vessels [6]. In aged mice (5 mg/kg i.p. every 2 days for 1 month), FOXO4-DRI reduced senescence markers in blood vessels and improved endothelial function.

Brain aging: Alameen et al. 2026

A recent review article discusses the potential of FOXO4-DRI and related senolytic peptides to mitigate brain aging and cognitive decline by eliminating senescent cells in the brain [8]. This is a theoretical perspective without its own experimental data in humans.

What risks and side effects are known?

The short answer: there are no human safety data for FOXO4-DRI. All statements about safety are based on mouse models and cell cultures that cannot be directly transferred to humans.

Nevertheless, some specific concerns are documented:

• Pulmonary hypertension: Born et al. (2023) showed that eliminating senescent cells can paradoxically promote the development and progression of pulmonary hypertension (high blood pressure in the lungs) [7]. Senescent cells apparently also serve protective functions, and their removal is not beneficial in every tissue.
• Off-target effects: The selectivity of FOXO4-DRI for senescent cells is demonstrated in cell cultures, but at higher doses or with chronic use, healthy cells could also be affected. Systematic studies on this are lacking.
• D-amino acids and immunogenicity: Since FOXO4-DRI consists of D-amino acids that do not normally occur in the body, the immune system could recognize the peptide as foreign and trigger an immune response. However, this has not been studied.
• Missing pharmacokinetics: Half-life, distribution in the body, breakdown, and excretion in humans are unknown. The intraperitoneal administration used in studies is not common in humans.

If you're generally interested in risks and safety aspects of peptides on the gray market, you can find more information in the peptide library and the glossary.

What is still unknown?

The research gaps for FOXO4-DRI are considerable:

• No human studies: There is not a single clinical study in humans, and none is registered (as of 2026).
• No dose finding: Even in animal models, a dose-response relationship has never been investigated. Whether 5 mg/kg in mice is optimal, too low, or too high is unknown.
• No long-term data: The longest observation period in the studies was about 30 days. What happens with repeated use over months or years is completely unclear.
• No subcutaneous bioavailability: All studies used i.p. or i.v. Whether subcutaneous injection (as commonly done on the gray market) is even effective has not been studied.
• Chronic senescence elimination: The repeated removal of senescent cells over long periods could have unexpected consequences, since senescent cells also fulfill functions in wound healing, tumor suppression, and tissue renewal.